Trial · NCT00101647
Results by group162
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 162
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Major and Overall Hematologic Response (MaHR and OHR) | Imatinib-intolerant | MaHR | 9 | participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Imatinib-resistant | MaHR | 103 | participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Total | MaHR | 112 | participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Imatinib-intolerant | OHR | 12 | participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Imatinib-resistant | OHR | 127 | participants | |
| Major and Overall Hematologic Response (MaHR and OHR) | Total | OHR | 139 | participants | |
| Percentage of Participants Who Achieved MaHR and Did Not Progress at 12 Months (Based on the Kaplan-Meier Estimate of the Duration of Response) | Imatinib-intolerant | 85.7 | percentage of responders | ||
| Percentage of Participants Who Achieved MaHR and Did Not Progress at 12 Months (Based on the Kaplan-Meier Estimate of the Duration of Response) | Imatinib-resistant | 78.3 | percentage of responders | ||
| Percentage of Participants Who Achieved MaHR and Did Not Progress at 12 Months (Based on the Kaplan-Meier Estimate of the Duration of Response) | Total | 79.0 | percentage of responders | ||
| Percentage of Participants Who Achieved MaHR and Did Not Progress at 24 Months in the Imatinib-Resistant Group (Based on the Kaplan-Meier Estimate of the Duration of Response) | Imatinib-resistant | 60.9 | percentage of responders | ||
| Percentage of Participants Who Achieved MaHR and Did Not Progress at 24 Months in the Imatinib-Resistant Group (Based on the Kaplan-Meier Estimate of the Duration of Response) | Total | 59.6 | percentage of responders | ||
| Percentage of Participants Who Achieved OHR and Did Not Progress at 12 Months and 24 Months | Imatinib-intolerant | OHR at 12 months | 69.8 | Percentage of responders | |
| Percentage of Participants Who Achieved OHR and Did Not Progress at 12 Months and 24 Months | Imatinib-resistant | OHR at 12 months | 69.7 | Percentage of responders | |
| Percentage of Participants Who Achieved OHR and Did Not Progress at 12 Months and 24 Months | Total | OHR at 12 months | 69.8 | Percentage of responders | |
| Percentage of Participants Who Achieved OHR and Did Not Progress at 12 Months and 24 Months | Imatinib-intolerant | OHR at 24 months | 34.9 | Percentage of responders | |
| Percentage of Participants Who Achieved OHR and Did Not Progress at 12 Months and 24 Months | Imatinib-resistant | OHR at 24 months | 51.2 | Percentage of responders | |
| Percentage of Participants Who Achieved OHR and Did Not Progress at 12 Months and 24 Months | Total | OHR at 24 months | 50.0 | Percentage of responders | |
| Median Time in Days From First Dosing Date to Date of MaHR | Imatinib-intolerant | 84 | Full Range 28 to 148 | Days | |
| Median Time in Days From First Dosing Date to Date of MaHR | Imatinib-resistant | 63 | Full Range 26 to 420 | Days | |
| Median Time in Days From First Dosing Date to Date of MaHR | Total | 65 | Full Range 26 to 420 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00101647/results